{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:51:18Z","timestamp":1769737878246,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["T32 CA090217"],"award-info":[{"award-number":["T32 CA090217"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA067264"],"award-info":[{"award-number":["R01 CA067264"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P20 GM103644"],"award-info":[{"award-number":["P20 GM103644"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005301","name":"American college of surgeons","doi-asserted-by":"crossref","award":["Resident Research Scholarship"],"award-info":[{"award-number":["Resident Research Scholarship"]}],"id":[{"id":"10.13039\/100005301","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10549-021-06278-5","type":"journal-article","created":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T11:02:39Z","timestamp":1623754959000},"page":"463-470","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?"],"prefix":"10.1007","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-0000","authenticated-orcid":false,"given":"Devon","family":"Livingston-Rosanoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Trentham-Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Hampton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polly A.","family":"Newcomb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee G.","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"issue":"1","key":"6278_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"issue":"41","key":"6278_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","volume":"2010","author":"C Correa","year":"2010","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Correa C, McGale P et al (2010) Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010(41):162\u2013177. https:\/\/doi.org\/10.1093\/jncimonographs\/lgq039","journal-title":"J Natl Cancer Inst Monogr."},{"issue":"3","key":"6278_CR3","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s10147-013-0575-0","volume":"19","author":"HX Bai","year":"2014","unstructured":"Bai HX, Motwani SB, Higgins SA et al (2014) Breast conservation therapy for ductal carcinoma in situ (DCIS): does presentation of disease affect long-term outcomes? Int J Clin Oncol 19(3):460\u2013466. https:\/\/doi.org\/10.1007\/s10147-013-0575-0","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"6278_CR4","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1200\/JCO.2011.36.4976","volume":"30","author":"M Yi","year":"2012","unstructured":"Yi M, Meric-Bernstam F, Kuerer HM et al (2012) Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision. J Clin Oncol 30(6):600\u2013607. https:\/\/doi.org\/10.1200\/JCO.2011.36.4976","journal-title":"J Clin Oncol"},{"issue":"1","key":"6278_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","volume":"12","author":"J Cuzick","year":"2011","unstructured":"Cuzick J, Sestak I, Pinder SE et al (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK\/ANZ DCIS trial. Lancet Oncol 12(1):21\u201329. https:\/\/doi.org\/10.1016\/S1470-2045(10)70266-7","journal-title":"Lancet Oncol"},{"issue":"32","key":"6278_CR6","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1200\/JCO.2014.56.2595","volume":"32","author":"F W\u00e4rnberg","year":"2014","unstructured":"W\u00e4rnberg F, Garmo H, Emdin S et al (2014) Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol 32(32):3613\u20133618. https:\/\/doi.org\/10.1200\/JCO.2014.56.2595","journal-title":"J Clin Oncol"},{"issue":"6","key":"6278_CR7","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/jnci\/djr027","volume":"103","author":"IL Wapnir","year":"2011","unstructured":"Wapnir IL, Dignam JJ, Fisher B et al (2011) Long-Term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. JNCI J Natl Cancer Inst 103(6):478\u2013488. https:\/\/doi.org\/10.1093\/jnci\/djr027","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"33","key":"6278_CR8","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1200\/JCO.2016.68.3573","volume":"34","author":"M Morrow","year":"2016","unstructured":"Morrow M, Van Zee KJ, Solin LJ et al (2016) Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on margins for breast-conserving surgery with whole-breast irradiation in ductal carcinoma in situ. J Clin Oncol 34(33):4040\u20134046. https:\/\/doi.org\/10.1200\/JCO.2016.68.3573","journal-title":"J Clin Oncol"},{"issue":"12","key":"6278_CR9","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1245\/s10434-016-5446-2","volume":"23","author":"ML Marinovich","year":"2016","unstructured":"Marinovich ML, Azizi L, Macaskill P et al (2016) The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 23(12):3811\u20133821. https:\/\/doi.org\/10.1245\/s10434-016-5446-2","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"6278_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/jnci\/djs142","volume":"104","author":"S-Y Wang","year":"2012","unstructured":"Wang S-Y, Chu H, Shamliyan T et al (2012) Network meta-analysis of margin threshold for women with ductal carcinoma in situ. JNCI J Natl Cancer Inst 104(7):507\u2013516. https:\/\/doi.org\/10.1093\/jnci\/djs142","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"1","key":"6278_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/SLA.0000000000002439","volume":"269","author":"AB Tadros","year":"2019","unstructured":"Tadros AB, Smith BD, Shen Y et al (2019) Ductal carcinoma in situ and margins <2 mm: contemporary outcomes with breast conservation. Ann Surg 269(1):150\u2013157. https:\/\/doi.org\/10.1097\/SLA.0000000000002439","journal-title":"Ann Surg"},{"issue":"2","key":"6278_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-010-0869-0","volume":"124","author":"BL Sprague","year":"2010","unstructured":"Sprague BL, Trentham-Dietz A, Nichols HB, Hampton JM, Newcomb PA (2010) Change in lifestyle behaviors and medication use after a diagnosis of ductal carcinoma in situ. Breast Cancer Res Treat 124(2):487\u2013495. https:\/\/doi.org\/10.1007\/s10549-010-0869-0","journal-title":"Breast Cancer Res Treat"},{"key":"6278_CR13","unstructured":"Rural-Urban Commuting Area Codes Data. https:\/\/depts.washington.edu\/uwruca\/ruca-uses.php"},{"key":"6278_CR14","doi-asserted-by":"publisher","unstructured":"Bouganim N, Tsvetkova E, Clemons M, Amir E (2013) Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research. Breast Cancer Res Treat 139(2):603\u2013606. https:\/\/doi.org\/10.1007\/s10549-013-2561-7","DOI":"10.1007\/s10549-013-2561-7"},{"key":"6278_CR15","doi-asserted-by":"publisher","unstructured":"Beatty JD, Sun Q, Markowitz D, Chubak J, Huang B, Etzioni R (2021) Identifying breast cancer recurrence histories via patient-reported outcomes. J Cancer Surviv. https:\/\/doi.org\/10.1007\/s11764-021-01033-7","DOI":"10.1007\/s11764-021-01033-7"},{"issue":"4","key":"6278_CR16","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/SLA.0000000000001454","volume":"262","author":"KJ Van Zee","year":"2015","unstructured":"Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M (2015) Relationship between margin width and recurrence of ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery for 30 years. Ann Surg 262(4):623\u2013631. https:\/\/doi.org\/10.1097\/SLA.0000000000001454","journal-title":"Ann Surg"},{"issue":"10","key":"6278_CR17","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1200\/JCO.2008.17.5182","volume":"27","author":"C Dunne","year":"2009","unstructured":"Dunne C, Burke JP, Morrow M, Kell MR (2009) Effect of margin status on local recurrence after breast conservation and radiation therapy for ductal carcinoma in situ. J Clin Oncol 27(10):1615\u20131620. https:\/\/doi.org\/10.1200\/JCO.2008.17.5182","journal-title":"J Clin Oncol"},{"issue":"33","key":"6278_CR18","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","volume":"33","author":"LJ Solin","year":"2015","unstructured":"Solin LJ, Gray R, Hughes LL et al (2015) Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol 33(33):3938\u20133944. https:\/\/doi.org\/10.1200\/JCO.2015.60.8588","journal-title":"J Clin Oncol"},{"issue":"7","key":"6278_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2014.57.9029","volume":"33","author":"B McCormick","year":"2015","unstructured":"McCormick B, Winter K, Hudis C et al (2015) RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33(7):709\u2013715. https:\/\/doi.org\/10.1200\/JCO.2014.57.9029","journal-title":"J Clin Oncol"},{"key":"6278_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.breast.2018.07.007","volume":"42","author":"JJ Jobsen","year":"2018","unstructured":"Jobsen JJ, Scheijmans LJEE, Smit WGJM, Stenfert Kroese MC, Struikmans H, van der Palen J (2018) Breast-conserving therapy for primary Ductal Carcinoma in Situ in The Netherlands: a multi-center study and population-based analysis. Breast 42:3\u20139. https:\/\/doi.org\/10.1016\/j.breast.2018.07.007","journal-title":"Breast"},{"key":"6278_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70277-1","author":"HM Kuerer","year":"2011","unstructured":"Kuerer HM (2011) Rational individualised selection of adjuvant therapy for ductal carcinoma in situ. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(10)70277-1","journal-title":"Lancet Oncol"},{"issue":"19","key":"6278_CR22","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836\u20131846. https:\/\/doi.org\/10.1056\/NEJMoa1701830","journal-title":"N Engl J Med"},{"issue":"45","key":"6278_CR23","doi-asserted-by":"publisher","first-page":"79257","DOI":"10.18632\/oncotarget.17366","volume":"8","author":"L Wang","year":"2017","unstructured":"Wang L, Xia Y, Liu D et al (2017) Evaluating the efficacy of post-surgery adjuvant therapies used for ductal carcinoma in situ patients: a network meta-analysis. Oncotarget 8(45):79257\u201379269. https:\/\/doi.org\/10.18632\/oncotarget.17366","journal-title":"Oncotarget"},{"issue":"1","key":"6278_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1186\/s12885-015-1904-7","volume":"15","author":"KE Stuart","year":"2015","unstructured":"Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J (2015) Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer 15(1):890. https:\/\/doi.org\/10.1186\/s12885-015-1904-7","journal-title":"BMC Cancer"},{"issue":"1","key":"6278_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10549-013-2670-3","volume":"141","author":"BL Sprague","year":"2013","unstructured":"Sprague BL, McLaughlin V, Hampton JM, Newcomb PA, Trentham-Dietz A (2013) Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study. Breast Cancer Res Treat 141(1):145\u2013154. https:\/\/doi.org\/10.1007\/s10549-013-2670-3","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6278_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s11764-014-0365-3","volume":"8","author":"SB Wheeler","year":"2014","unstructured":"Wheeler SB, Kohler RE, Reeder-Hayes KE et al (2014) Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. J Cancer Surviv 8(4):603\u2013610. https:\/\/doi.org\/10.1007\/s11764-014-0365-3","journal-title":"J Cancer Surviv"},{"issue":"27","key":"6278_CR27","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","volume":"28","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28(27):4120\u20134128. https:\/\/doi.org\/10.1200\/JCO.2009.25.9655","journal-title":"J Clin Oncol"},{"issue":"21","key":"6278_CR28","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1200\/JCO.2008.19.2419","volume":"27","author":"G Kimmick","year":"2009","unstructured":"Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R (2009) Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol 27(21):3445\u20133451. https:\/\/doi.org\/10.1200\/JCO.2008.19.2419","journal-title":"J Clin Oncol"},{"key":"6278_CR29","doi-asserted-by":"publisher","unstructured":"DeCensi A, Puntoni M, Guerrieri-Gonzaga A et al (2019) Randomized placebo controlled trial of low-dose tamoxifen to prevent local and contralateral recurrence in breast intraepithelial neoplasia. J Clin Oncol 37(19):1629\u20131637. https:\/\/doi.org\/10.1200\/JCO.18.01779","DOI":"10.1200\/JCO.18.01779"},{"key":"6278_CR30","doi-asserted-by":"publisher","unstructured":"The Consensus Conference Committee (1997) Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer 80(9):1798\u20131802. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(19980601)82:11<2293::AID-CNCR29>3.0.CO;2-O","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2293::AID-CNCR29>3.0.CO;2-O"},{"issue":"4","key":"6278_CR31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.5858\/arpa.2016-0626-CP","volume":"142","author":"AJ Guidi","year":"2018","unstructured":"Guidi AJ, Tworek JA, Mais DD, Souers RJ, Blond BJ, Brown RW (2018) Breast specimen processing and reporting with an emphasis on margin evaluation: a college of american pathologists survey of 866 laboratories. Arch Pathol Lab Med 142(4):496\u2013506. https:\/\/doi.org\/10.5858\/arpa.2016-0626-CP","journal-title":"Arch Pathol Lab Med"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06278-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06278-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06278-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T06:07:33Z","timestamp":1628662053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06278-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["6278"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06278-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,15]]},"assertion":[{"value":"23 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LGW is a founder and minority stock owner of Elucent Medical. LGW is the PI of a margin assessment device trial for Perimeter; she does not receive any salary support for this work but her institution receives payment for patient accrual.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the University of Wisconsin Health Sciences Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All study participants provided informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have read the paper and consent to its publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}